OSLO/LONDON, 8 June 2022: EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth:
EXTX), a clinical stage biopharmaceutical company with a mission to enhance the
therapeutic efficacy of medicines through ultrasound-mediated drug delivery,
today announces that Anders Wold, Board Director since December 2021, has been
appointed Chair of the Board, with immediate effect.
Anders Wold started his career in the field of medical ultrasound in 1984 as he
joined the start-up Vingmed which was acquired in 1998 by GE Healthcare. He has
nearly forty years of leadership experience in the healthcare and ultrasound
industry including President and CEO of GE Healthcare Clinical Care Solutions.
The current Executive Chair of the Board, Dr Masha Strømme will assume the role
of Vice-Chair of the Board. Sir William Castell, current Vice-Chair of the
Board, will assume the role of Director of the Board alongside Dr Jean-Michel
Cosséry and Ann-Tove Kongsnes. Dr Aitana Peire did not seek re-election and on
behalf of the shareholders, the Board of Directors would like to thank her for
her support and excellent contribution.
Dr Masha Strømme, Executive Chair of the Board, commented: "We are delighted
that Anders has accepted the role of Chair of the Board. He brings considerable
experience in global markets and the Company will benefit tremendously from his
leadership as we look to expand the clinical trials and development of the ACT®
technology platform in the years ahead."
Anders Wold, Director of the Board, stated: "These are exciting times for
EXACT-Tx. ACT® is a unique technology in the crossover between Bio Pharma and
Med Tech. I feel very privileged to take on this role at such an exciting time
in the Company's journey towards becoming a leading precision health company."
For more information, please contact:
Per Walday, CEO
EXACT-Tx is a Norwegian clinical-stage precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101)
activated by ultrasound for enhanced drug targeting deployed in multiple
indications to enhance the therapeutic efficacy of medicines through the use of
ultrasound-mediated drug delivery, for patients across multiple diseases.
Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.